13F-HR filed by GREAT POINT PARTNERS LLC
GREAT POINT PARTNERS LLC filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 40 holding rows worth $415,311,000.
- Accession
- 0001172661-22-002573
- Filer
- CIK 1281446
- Filed
- 2022-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2022
A holdings report, 40 entries on the cover page, a total value of $415,311,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $415,311,000 with VALUE read as thousands by filing date, 13F file number 028-11743. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerJAY JEFFREY R028-12517
- included managerYehudai Ortav028-20398
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 850,000 | $30,685,000 | thousands by filing date | |
| JAZZ PHARMACEUTICALS PLC SHS USD | G50871105 | Stock | 215,000 | $28,657,000 | thousands by filing date | |
| POINT BIOPHARMA GLOBAL INC | 730541109 | COM | 3,560,984 | $27,526,000 | thousands by filing date | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 3,448,521 | $24,829,000 | thousands by filing date | |
| TRAVERE THERAPEUTICS INC | 89422G107 | COM | 966,108 | $23,805,000 | thousands by filing date | |
| HERON THERAPEUTICS INC | 427746102 | COM | 5,645,161 | $23,484,000 | thousands by filing date | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 1,551,719 | $22,515,000 | thousands by filing date | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 1,041,737 | $21,762,000 | thousands by filing date | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 510,000 | $18,880,000 | thousands by filing date | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 1,019,282 | $16,043,000 | thousands by filing date | |
| VAXCYTE INC COM | 92243G108 | Stock | 600,000 | $14,400,000 | thousands by filing date | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 306,411 | $13,065,000 | thousands by filing date | |
| ACUMEN PHARMACEUTICALS INC | 00509G209 | CMN | 1,200,000 | $12,036,000 | thousands by filing date | |
| ALKERMES PLC | G01767105 | SHS | 507,500 | $11,332,000 | thousands by filing date | |
| SEAGEN INC | 81181C104 | COM | 76,500 | $10,467,000 | thousands by filing date | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 1,050,000 | $10,437,000 | thousands by filing date | |
| CINCOR PHARMA INC | 17240Y109 | COM | 301,324 | $9,889,000 | thousands by filing date | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 269,967 | $9,425,000 | thousands by filing date | |
| TRICIDA INC | 89610F101 | COM | 870,000 | $9,118,000 | thousands by filing date | |
| RAPT THERAPEUTICS INC | 75382E109 | COM | 315,000 | $7,579,000 | thousands by filing date | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 873,424 | $7,267,000 | thousands by filing date | |
| REPLIMUNE GROUP INC | 76029N106 | COMMON STOCK | 390,000 | $6,735,000 | thousands by filing date | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 95,500 | $6,207,000 | thousands by filing date | |
| Milestone Pharmaceuticals Inc | 59935V107 | COM | 674,656 | $6,200,000 | thousands by filing date | |
| 89BIO INC | 282559103 | COM | 955,000 | $5,529,000 | thousands by filing date | |
| GENERATION BIO CO | 37148K100 | COM | 825,077 | $4,381,000 | thousands by filing date | |
| NGM BIOPHARMACEUTICALS INC | 62921N105 | COM | 316,256 | $4,137,000 | thousands by filing date | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 492,000 | $3,818,000 | thousands by filing date | |
| IMMUNOCORE HLDGS PLC ADS | 45258D105 | ADR | 78,527 | $3,686,000 | thousands by filing date | |
| LARIMAR THERAPEUTICS INC | 517125100 | COM | 1,135,000 | $3,632,000 | thousands by filing date | |
| PRECISION BIOSCIENCES INC | 74019P108 | COM | 2,710,805 | $3,524,000 | thousands by filing date | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 799,439 | $2,798,000 | thousands by filing date | |
| PIERIS PHARMACEUTICALS INC | 720795103 | COM | 1,965,449 | $2,260,000 | thousands by filing date | |
| INTERCEPT PHARMACEUTICALS IN | 45845P108 | COM | 105,000 | $1,465,000 | thousands by filing date | |
| GRACELL BIOTECHNOLOGIES INC | 38406L103 | ADR | 449,049 | $1,446,000 | thousands by filing date | |
| DIANTHUS THERAPEUTICS INC COM | 55910K108 | Stock | 1,019,091 | $1,437,000 | thousands by filing date | |
| NEKTAR THERAPEUTICS | 640268108 | COM | 447,820 | $1,433,000 | thousands by filing date | |
| Day One Biopharmaceuticals Inc | 23954D109 | Common Stock | 70,621 | $1,415,000 | thousands by filing date | |
| AEGLEA BIOTHERAPEUTICS INC | 00773J103 | COM | 2,500,000 | $1,315,000 | thousands by filing date | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 68,915 | $692,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001172661-22-002573 | this filing | 2022-11-14 | acceptance time not in the bulk data set |